[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-disease-and-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-disease-and-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100617010","chapter-clonal-haematopoiesis-assessment-prevention-treatment-and-research-100617010",false,"NCT07313059","CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research","Prospective Clinical Evaluation of Incidence, Outcomes and Individuals Experiences Following Diagnosis of Clonal Haematopoiesis in a Dedicated Research Clinic","CHAPTER","Inclusion Criteria:\n\n1. Aged 55 years and above\n2. Confirmed CH or possible CH, with possible CH defined by:\n\n   a. Persistent, non-severe cytopenia, characterised by one or more of the following, present on at least 2 occasions, at least 4 months apart (WHO criteria): i. Absolute neutrophil count (ANC) \\\u003C 1.8 x 109\u002FL ii. Haemoglobin (Hb) \\\u003C 120 g\u002FL in females, \\\u003C 130 g\u002FL in males iii. Platelet count \\\u003C 150 x 109\u002FL\n3. Provision of written informed consent prior to any study-related assessments or procedures being carried out.\n\nExclusion Criteria:\n\n1. Severe cytopenia as defined by one or more of the following:\n\n   1. ANC \\\u003C 0.5 x109\u002FL\n   2. Hb \\\u003C 80 g\u002FL\n   3. Platelet count \\\u003C 50 x 109\u002FL\n2. Multilineage cytopenias:\n\n   a. Marked trilineage cytopenia with all the following present: i. ANC \\\u003C 1.0 x 109\u002FL AND ii. Hb \\\u003C 110 g\u002FL AND iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   b. Marked bilineage cytopenia, with two or more of the following present: i. ANC \\\u003C 1.0 x 109\u002FL ii. Hb \\\u003C 110 g\u002FL iii. Platelet count \\\u003C 100 x 109\u002FL\n\n   Note: People with possible CH, with the above characteristics will be excluded from referral to the CH clinic and will instead have urgent investigation as an inpatient or in the haematology clinic. However, if no definite cause for cytopenia is identified, including CH, then individuals may be referred for CH screening at the CH clinic the discretion of the study PI","ALL","55 Years",{"count":20,"type":21},100,"ESTIMATED","5 Years","OBSERVATIONAL","People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.\n\nIndividuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.\n\nResearchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.\n\nThe information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.\n\nParticipants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.",[26,27,28],"Clonal Hematopoiesis","CCUS Clonal Cytopenia of Undetermined Significance","Hematologic Disease and Disorders",[26,30,31],"CH","CCUS","RECRUITING","2026-05-11",{"date":35,"type":36},"2026-05-13","ACTUAL",{"date":38,"type":36},"2026-03-20",{"date":40,"type":21},"2033-11",{"name":42,"class":43},"Clinical Hub for Interventional Research (CHOIR)","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":74,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100598722","phase-1-a-study-to-evaluate-a-novel-gene-therapy-in-patients-with-relapsed-and-refractory-multiple-myeloma-100598722","NCT07075185","A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma","inMMyCAR","Inclusion Criteria:\n\n* Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease\n* Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody\n* Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1\n* Participants must have acceptable laboratory values as defined by the protocol\n\nExclusion Criteria:\n\n* Participants must not have known central nervous system (CNS) involvement with myeloma\n* Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis\n* Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy\n* Participants cannot require systemic steroids for any condition","18 Years",{"count":55,"type":21},70,"INTERVENTIONAL",[58],"PHASE1","The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.",[61,62,63,64,65,66,67,68,69,28,70,71,72,73],"Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy",[75,76,77,78],"in vivo CAR-T","multiple myeloma","gene therapy","BMCA","2026-04-22",{"date":81,"type":36},"2026-04-24",{"date":83,"type":36},"2025-07-16",{"date":85,"type":21},"2042-05",{"name":87,"class":88},"Kelonia Therapeutics, Inc.","INDUSTRY",7,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":56,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":44},"100579784","phase-2-early-use-of-tacrolimus-in-hla-mismatched-haploidentical-allogeneic-hematopoietic-transplantation-with-post-transplant-cyclophosphamide-100579784","NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","80 Years",{"count":98,"type":21},20,[100],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[28,103],"Hematopoietic Cell Transplant","2026-04-15",{"date":106,"type":36},"2026-04-16",{"date":108,"type":36},"2025-07-03",{"date":110,"type":21},"2028-06-30",{"name":112,"class":113},"Northside Hospital, Inc.","OTHER"]